Literature DB >> 2652188

A general overview of amiodarone toxicity: its prevention, detection, and management.

T R Vrobel1, P E Miller, N D Mostow, L Rakita.   

Abstract

Although amiodarone is a highly effective antiarrhythmic agent, it has a high incidence of side effects, some of which can be serious or even lethal. With close monitoring, side effects can be found in essentially all patients, but fortunately most of these are mild and well tolerated. Furthermore, many will respond to dosage reduction in a relatively short period of time, ie, days to weeks, which is remarkable considering the long period of time amiodarone has been shown to persist in tissues. There is reasonable evidence that toxicity, particularly the early toxic manifestations with large loading dosages, can be favorably modified by reducing the dosage. Similarly, reducing the maintenance dosage will, in most instances, reduce or eliminate most toxic manifestations. The mechanisms of toxic effects are uncertain, but suggestive evidence exists for and against both an immunologic reaction and an intracellular lysosomal lipoidosis. Principles of use of amiodarone should include individualizing administration of dosages for each patient due to the unusual pharmacokinetic properties of this drug and continuous long-term attempts at using the lowest effective dosage. There are no definite tests that predict amiodarone efficacy or toxicity, but the serum level can be used as a rough guide of absorption and distribution in the attempt to minimize the maintenance dosage. No guidelines regarding screening tests for toxicity can be made at this time since great variability in these tests has been reported, and no evidence exists for their benefit in preventing adverse effects to amiodarone. However, follow-up testing at the intervals noted in the package insert are reasonable and important. The possibility of interactions with drugs already reported and with others not yet reported should always be kept in mind, and appropriate monitoring for clinical evidence of toxicity due to the concomitantly used drugs should be undertaken. Amiodarone can have a tremendous beneficial effect in the proper circumstances, but it is a drug that should command utmost respect because of its side effects and requires constant vigilance from any physician wishing to use it.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652188     DOI: 10.1016/0033-0620(89)90016-9

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  15 in total

Review 1.  Controversial aspects of thyroid disease.

Authors:  F W Hanna; J H Lazarus; M F Scanlon
Journal:  BMJ       Date:  1999-10-02

Review 2.  An Update on the Energy Sources and Catheter Technology for the Ablation of Atrial Fibrillation.

Authors:  Pawan K Arora; James C Hansen; Adam D Price; Josef Koblish; Boaz Avitall
Journal:  J Atr Fibrillation       Date:  2010-03-01

3.  Amiodarone-associated bilateral vestibulopathy.

Authors:  Robert Gürkov; Leonardo Manzari; Alexander Blödow; Angela Wenzel; Dusan Pavlovic; Leonal Luis
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-27       Impact factor: 2.503

Review 4.  The clinical spectrum of amiodarone-associated optic neuropathy.

Authors:  Lenworth N Johnson; Gregory B Krohel; Eric R Thomas
Journal:  J Natl Med Assoc       Date:  2004-11       Impact factor: 1.798

5.  Use of plasma iodine assay for diagnosing thyroid disorders.

Authors:  P Allain; S Berre; N Krari; P Lainé-Cessac; A Le Bouil; N Barbot; V Rohmer; J C Bigorgne
Journal:  J Clin Pathol       Date:  1993-05       Impact factor: 3.411

Review 6.  Drug-induced thyroid disorders.

Authors:  N J Gittoes; J A Franklyn
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 7.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

8.  Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases.

Authors:  S Grosso; R Berardi; M Cioni; G Morgese
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  Side effects with amiodarone therapy.

Authors:  R Shukla; N I Jowett; D R Thompson; J E Pohl
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

10.  Spiral waves and reentry dynamics in an in vitro model of the healed infarct border zone.

Authors:  Marvin G Chang; Yibing Zhang; Connie Y Chang; Linmiao Xu; Roland Emokpae; Leslie Tung; Eduardo Marbán; M Roselle Abraham
Journal:  Circ Res       Date:  2009-10-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.